 |
200 Diseases |  |
192 Trials |
|
192 Trials |  |
21170 News |  |
| «12...161162163164165166167168169170171...224225» |
- | Plivensia (sirukumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, P3 data, Journal: Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial. (Pubmed Central) - Mar 31, 2020
No abstract available
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Biomarker, Journal: In vitro human helper T-cell assay to screen antibody drug candidates for immunogenicity. (Pubmed Central) - Mar 31, 2020
Biotherapeutics with low immunogenicity yielded values of 0% for basiliximab and 3.7% for etanercept...Calculations based on the data here showed that a T cell assay with 40 donors could provide statistically significant differences when comparing low- (etanercept) versus highly immunogenic mAb (except for infliximab). Based on the outcomes here, for screening purposes, a practical cutoff point of 3/20 positives with 20 donors was proposed to alert immunogenicity of mAb drug candidates.
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Journal: Analysis of four therapeutic monoclonal antibodies by online capillary isoelectric focusing directly coupled to quadrupole time-of-flight mass spectrometry. (Pubmed Central) - Mar 31, 2020
Two lysine clipping variants and a deamidated variant were observed in adalimumab...The mAb analyses demonstrated the feasibility of the cIEF-MS method, and they demonstrated how charge and structural variants and minor differences in therapeutic mAbs are observed with this technology. Online cIEF-MS is an information rich technology with high throughput, demonstrated by the initial data presented here.
- | Humira (adalimumab) / Eisai, AbbVie
Journal: Nanoparticle-delivered siRNA targeting Bruton's tyrosine kinase for rheumatoid arthritis therapy. (Pubmed Central) - Mar 31, 2020
Thereafter, we encapsulated siRNA targeting BTK (siBTK) into the CLANs, denoted as CLANsiBTK, and demonstrated that CLANsiBTK significantly inhibited BTK expression in macrophages and B cells. In a collagen-induced mouse arthritis model, CLANsiBTK treatment dramatically reduced joint inflammation and other RA symptoms but showed no toxicity, proving that using CLANsiBTK is a promising approach for RA therapy.
- | Humira (adalimumab) / Eisai, AbbVie
Journal: Secondary organizing pneumonia (bronchiolitis obliterans with organizing pneumonia) associated with adalimumab for treatment of chronic plaque psoriasis. (Pubmed Central) - Mar 31, 2020
Her biologic treatment was ceased and corticosteroid treatment commenced, with resolution of both her symptoms and the radiological findings. Given the increasing incidence of biologic treatment in the management of dermatological conditions, clinicians should be aware of secondary organizing pneumonia as a possible side effect of TNF inhibitor therapy.
- | Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Journal: Successful treatment of hidradenitis suppurativa in the setting of Crohn disease with combination adalimumab and ustekinumab. (Pubmed Central) - Mar 31, 2020
The patient re-started on adalimumab weekly and ustekinumab every 8 weeks. After one month, the patient reported clear improvement in her hidradenitis and Crohn disease with the combined therapy.
- || Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Adalimumab for severe psoriasis in Chilean paediatric patients. (Pubmed Central) - Mar 31, 2020
After one month, the patient reported clear improvement in her hidradenitis and Crohn disease with the combined therapy. No abstract available
- | Journal, HEOR: The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis. (Pubmed Central) - Mar 30, 2020
No abstract available The introduction of tildrakizumab with a 1% annual uptake over 5 years has the potential to reduce the cost of treating patients with moderate-to-severe plaque psoriasis for a US health plan.
- ||||||| etrolizumab (RG7413) / Roche
Trial completion, Trial completion date: HIBISCUS I: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Mar 30, 2020
P3, N=358, Completed, Sponsor: Hoffmann-La Roche
The introduction of tildrakizumab with a 1% annual uptake over 5 years has the potential to reduce the cost of treating patients with moderate-to-severe plaque psoriasis for a US health plan. Active, not recruiting --> Completed | Trial completion date: Jul 2020 --> Mar 2020
- | Review, Journal: Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. (Pubmed Central) - Mar 29, 2020
The results indicated that brodalumab had a similar probability of response to ixekizumab, secukinumab and infliximab and a higher probability of response than ustekinumab, adalimumab, etanercept, apremilast, dimethyl fumarate and placebo...Brodalumab is recommended as an option for treating adults with severe plaque psoriasis (defined by a total Psoriasis Area and Severity Index score of 10 or more and a Dermatology Life Quality Index score of more than 10) who have not responded to other systemic non-biological therapies. Brodalumab should be stopped at 12 weeks if the psoriasis has not responded adequately.
- || Remicade (infliximab) / Mitsubishi Tanabe, J&J, Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / Eisai, AbbVie
Retrospective data, Review, Journal: Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis. (Pubmed Central) - Mar 29, 2020
Based on our findings, we recommend a preliminary course of action regarding immunogenicity of biologic agents in patients with JIA. Further strategies to predict, prevent, detect and manage immunogenicity could optimize treatment outcomes and personalize treatment with biologic therapies.
- | Humira (adalimumab) / Eisai, AbbVie
Journal: Adalimumab- Induced Scalp Psoriasis with Severe Alopecia. (Pubmed Central) - Mar 29, 2020
We conclude that, in anti-TNF-?-induced scalp psoriasis, suspension of anti-TNF- ? agent and systemic and topical treatments should be considered in order to avoid scarring alopecia.
- | Humira (adalimumab) / Eisai, AbbVie
Journal: Hidradenitis suppurativa in a prepubertal girl. (Pubmed Central) - Mar 29, 2020
We report the case of a 10-year-old girl with Hurley III HS, refractory to multiple topical and systemic therapies. After introducing adalimumab, there was significant improvement of the skin lesions and therefore in the child's quality of life.
- || Taltz (ixekizumab) / Eli Lilly, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal, HEOR, Real-World Evidence: Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab. (Pubmed Central) - Mar 28, 2020
Psoriasis patients treated with ixekizumab demonstrated longer persistency, higher adherence and were less likely to discontinue or switch treatment compared to adalimumab users. However, while patients achieving highly adherent threshold significantly differed by MPR ≥80%, it did not by PDC ≥80%; hence, further analysis using fixed-length follow-up is required.
- | Humira (adalimumab) / Eisai, AbbVie
Biomarker, Journal: Circulating Retinol-Binding Protein 4 as a Possible Biomarker of Treatment Response for Ankylosing Spondylitis: An Array-Based Comparative Study. (Pubmed Central) - Mar 28, 2020
To explore proteins associated with ankylosing spondylitis (AS) and to investigate potential proteins that may predict treatment response of adalimumab (ADA) in AS patients...ADA exerted a considerable but not entire alteration toward the dysregulation. RBP4 could be a biomarker for predicting and monitoring ADA treatment response.
- |||| Humira (adalimumab) / Eisai, AbbVie
Adverse events: My teen son w/ Crohn’s just diagnosed w/ Costrochondritis side effect from an unknown virus. Had COVID19 symptoms but was not tested due to shortage of tests & clear chest X-ray. GI doc @ Mt Sinai NYC said to hold off on Humira until he is better. (Twitter) - Mar 27, 2020
- | Humira (adalimumab) / AbbVie
Enrollment open: Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial (clinicaltrials.gov) - Mar 27, 2020
P4, N=315, Recruiting, Sponsor: University of Oxford
RBP4 could be a biomarker for predicting and monitoring ADA treatment response. Not yet recruiting --> Recruiting
- || Remicade (infliximab) / Mitsubishi Tanabe, J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: The Effect of Biologics on Post-Operative Complications in Children with Inflammatory Bowel Disease and Bowel Resection. (Pubmed Central) - Mar 26, 2020
The number of complications was the same between those who did and did not receive a preoperative biologic agent. This study suggests that biologics may be safe to use in patients undergoing bowel resection.
- ||| Humira (adalimumab) / Eisai, AbbVie
Adalimumab ?? Is this being considered a treatment option in #COVID19? Rationale ? (Twitter) - Mar 26, 2020
- || Remicade (infliximab) / Mitsubishi Tanabe, J&J, Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Pricing, Journal, HEOR: Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients. (Pubmed Central) - Mar 26, 2020
For moderate-severe Crohn's disease, infliximab yields slightly more NMBs compared with both adalimumab and ustekinumab. Additional clinical (e.g., empiric dosing, biologic cycling) and quality-of-life (e.g., lost productivity, disutility of home injections) research is needed to allow for model frameworks and parameters that more accurately reflect the nuances of Crohn's disease treatment.
- ||| Clinical, Journal, Adverse events, Real-World Evidence: Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. (Pubmed Central) - Mar 26, 2020
Due to the voluntary nature of FAERS, this finding should be considered hypothesis generating (rather than hypothesis testing). Longer-term observational studies are required to evaluate the safety of vedolizumab.
- ||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
@IBDMD I have Crohn’s disease and I am beyond afraid to go in for a remicade infusion. I do not want to be exposed to even the infusion nurse. I am on 800mg every 4 weeks ( to keep remicade antibodies away) Humira is not an option because I developed antibodies. (Twitter) - Mar 26, 2020
- ||| Humira (adalimumab) / AbbVie
Trial completion: Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA ) (clinicaltrials.gov) - Mar 26, 2020
P=N/A, N=98, Completed, Sponsor: AbbVie
Longer-term observational studies are required to evaluate the safety of vedolizumab. Active, not recruiting --> Completed
- | Retrospective data, Journal: Treatment sequence network-meta analysis in Crohn's disease: a methodological case study. (Pubmed Central) - Mar 26, 2020
The NMA suggest that ustekinumab is associated with the highest likelihood of reaching response or remission at 1 year compared with placebo, adalimumab, and vedolizumab. Results should be interpreted with caution because this is a novel methodology; however, the treatment sequence analysis may be the most methodologically sound analysis to derive estimates of comparative efficacy in CD in the absence of head-to-head evidence.
- |||| budesonide / Generic mfg., Humira (adalimumab) / Eisai, AbbVie
Clinical: I had one case: women w severe diarrhea with appearance of linear cat scratches-like of the colon , not typical for Crohn's ; Biospies with increased IEL and collagenous membrane. Didnt respond to budesonide and responded to adalimumab. #GIJournalClub (Twitter) - Mar 25, 2020
- ||| Humira (adalimumab) / Eisai, AbbVie
Clinical: I was going to ask this exact question - I am 29 weeks preg, on humira, with UC in remission. Have only been leaving the house for prenatal appointments and nothing else for 1 month already. Have been so afraid - I hope we get more info soon. Really appreciating your updates! (Twitter) - Mar 25, 2020
- || Humira (adalimumab) / Eisai, AbbVie
That’s my problem work in refrigeration for supermarkets etc so going to places lots of people wanting to go to I’ve had no letter saying I’m at risk but taking humira currently booked this week off to see what I’m going to do stuck between a rock and a hard place (Twitter) - Mar 25, 2020
- || Humira (adalimumab) / Eisai, AbbVie
What about if you're taking stronger doses of your biologic? I'm on weekly Humira and the normal dosage is biweekly. (Twitter) - Mar 25, 2020
- || Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Review, Journal, HEOR, Real-World Evidence: Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies. (Pubmed Central) - Mar 25, 2020
Moreover, it supports the view that combination therapy with an immunomodulator prolongs the durability of IFX therapy in patients who previously failed to recover following first-line therapy. The limited number of time-to-event studies in patients on ADA prevented us from drawing definite conclusions about its long-term efficacy.
- | Journal: Fever During Anti-integrin Therapy: New Immunodeficiency. (Pubmed Central) - Mar 25, 2020
In the past he had already taken infliximab, adalimumab and golimumab without any clinical response...This was successfully treated with intravenous ganciclovir therapy...Moreover, it should always be remembered that IBD patients have an increased risk of CMV infection, both primary and reactivation, because of their concurrent immunosuppression. It is important to consider CMV infection (primary and reactivation) in patients affected by IBD.
- | Reimbursement, Journal: Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. (Pubmed Central) - Mar 24, 2020
This US-based healthcare policy analysis points to an increased access to advanced therapies for UC and CD. An individualized, risk-stratified treatment approach integrating advanced therapies, including those recently approved, into treatment pathways for UC and CD is feasible.
- | Humira (adalimumab) / Eisai, AbbVie
Journal: Adalimumab in juvenile-idiopathic arthritis-associated uveitis (JIA-U): 5-year follow-up of the Bristol participants of the SYCAMORE trial. (Pubmed Central) - Mar 24, 2020
Drug-induced remission of JIA-U did not persist when adalimumab was withdrawn after 1-2 years treatment. Adalimumab was well tolerated and visual acuity outcomes were excellent.
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Journal: Simultaneous Quantification of Free Adalimumab and Infliximab in Human Plasma Using a Target-Based Sample Purification and Liquid Chromatography-Tandem Mass Spectrometry. (Pubmed Central) - Mar 24, 2020
Adalimumab was well tolerated and visual acuity outcomes were excellent. This method provides an easy, efficient, and cost-effective workflow for therapeutic drug monitoring patients treated with ADM or IFX.
- ||| Humira (adalimumab) / Eisai, AbbVie
Hi, I would recommend taking a look at the guidance that the @BritSocGastro put out (see below - Adalimumab appears in the moderate risk category) and if you have further questions, please check in with your care team. Be well! (Twitter) - Mar 24, 2020
- || Humira (adalimumab) / Eisai, AbbVie
Hi I am in the UK and taking Humira but I haven't been told if this makes me more vulnerable to this virus. I am staying at home and not going out (Twitter) - Mar 24, 2020
- | Humira (adalimumab) / AbbVie
Enrollment open: Adalimumab in JIA-associated Uveitis Stopping Trial (clinicaltrials.gov) - Mar 24, 2020
P3, N=118, Recruiting, Sponsor: Nisha Acharya
This method provides an easy, efficient, and cost-effective workflow for therapeutic drug monitoring patients treated with ADM or IFX. Not yet recruiting --> Recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
Hi so if I have hypertension and take adalimumab ( managed by heath care at home ) would you say I can expect a letter regarding 12 week shielding ? Any help appreciated (Twitter) - Mar 24, 2020
- || Humira (adalimumab) / Eisai, AbbVie
What if you're taking Humira weekly? Does that change the risk category? And what is enhanced social distancing? (Twitter) - Mar 23, 2020
- || Humira (adalimumab) / Eisai, AbbVie
@IBDMD @VicentHernande9 @DCharabaty Follow up. She completed 10d oral vanco. Got loading 160mg HUMIRA. Doing better. Started steroid taper. I am tempted to give the 80mg dose on day 8 hoping it will assist speed up steroid taper Yes/No? (Twitter) - Mar 23, 2020
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Trial initiation date: A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab (clinicaltrials.gov) - Mar 23, 2020
P=N/A, N=4540, Not yet recruiting, Sponsor: Sungkyunkwan University
Not yet recruiting --> Recruiting Initiation date: Jan 2020 --> Apr 2020
- || Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission. (Pubmed Central) - Mar 23, 2020
Higher adalimumab levels are associated with biologic remission. An optimal level of >8.5 µg/mL was identified.
- || Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical, Review, Journal: Characterization of auto-immune hepatitis associated with the use of anti-TNFα agents: An analysis of 389 cases in VigiBase. (Pubmed Central) - Mar 22, 2020
The most frequent reported indication for anti-TNF-α agent was rheumatoid arthritis (31.9%). This study enables the identification and a detailed study of 389 new cases of ATIAIH and confirms a significant association of ATIAIH with infliximab, adalimumab and etanercept.
- Humira (adalimumab) / Eisai, AbbVie
Adalimumab for severe acne inversa: Not adequate? Surgery seems better! (e-Poster Hall) - Mar 21, 2020 - Abstract #EADVSp2020EADV-Sp_312;
- Humira (adalimumab) / Eisai, AbbVie
Recalcitrant cutaneous sarcoidosis - regarding a case treated with adalimumab (e-Poster Hall) - Mar 21, 2020 - Abstract #EADVSp2020EADV-Sp_310;
- ||| Humira (adalimumab) / Eisai, AbbVie
Zisman - the CREOLE study in #Crohns strictures showed that treatment w Adalimumab reduced the risk of progression to endoscopic dilation or surgery and increased the chance of being asymptomatic at 2 years VM #IBD 2020 (Twitter) - Mar 20, 2020
- ||| Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
Clinical: From a pharmacy perspective, we use this study to help get approval for Entyvio when a payor wants Humira to be used first line instead in tx of mod-severe UC. Entyvio has certain benefits so better option for certain patients! (Twitter) - Mar 20, 2020
- ||| Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
Head-to-Head: Agree with Varsity study. First head-to-head study of Humira and Entyvio 😍 hopefully paving the way for future head-to-head study for other biologics. https://t.co/BngLCAtuZY (Twitter) - Mar 20, 2020
- || Humira (adalimumab) / Eisai, AbbVie
Clinical, P4 data, Journal, Real-World Evidence: Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis. (Pubmed Central) - Mar 20, 2020
P=N/A
Adalimumab treatment improved WPAI in patients with PsA. Improvements in OWI and joint symptoms were significantly associated.
- || Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Anti-TNF alpha-induced eruptive nevi: Three cases (Pubmed Central) - Mar 20, 2020
EMN remains a rare phenomenon in patients on anti-TNF alpha. These cases, associated with the description of a moderate increased risk of developing cutaneous carcinoma under anti-TNF alpha, underscore the need for dermatological follow-up and increased sun protection in patients receiving this treatment.
- ||| Bimzelx (bimekizumab) / UCB
Enrollment change: A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. (clinicaltrials.gov) - Mar 20, 2020
P2, N=90, Completed, Sponsor: UCB Biopharma S.P.R.L.
These cases, associated with the description of a moderate increased risk of developing cutaneous carcinoma under anti-TNF alpha, underscore the need for dermatological follow-up and increased sun protection in patients receiving this treatment. N=157 --> 90